Monitoring multifunctionality of immune-exhausted CD8(+) T cells co-expressing Eomes and KIR/NKG2A in patients with solid tumors and CML will help to determine whether the evasion/subversion mechanisms used by tumor cells also apply to innate CD8(+) T cells in humans. This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.